Surgery--ComplicationsNCT04257344
Use of Wearables for Early Detection of Complications After Major Acute Abdominal Surgery
An observational study of Surgery--Complications and Abdomen Disease, run by Zealand University Hospital at 1 site in Denmark.
Trial summary
The purpose of the study is to investigate whether glucose profile, sleep disturbances and heart rate variability measured with wearable devices is associated with postoperative recovery and complications within 30 days after major emergency abdominal surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Surgery--Complications, Abdomen Disease
- How many people
- 40 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Oct 2019to 20 Feb 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: the study population consists of all patients admitted at Zealands University Hospital Køge, who undergo major emergency abdominal surgery.
Who may be able to join
- Patients undergoing major emergency abdominal surgery including laparotomy or laporoscopy. Indications include ileus, perforated hollow organ, intraabdominal bleeding, ischemia, wound dehiscence.
Who cannot join
- Laparoscopic surgeries for diseases related to appendix, gall bladder or bile ducts are excluded, unless the procedure is converted to open surgery perioperative.
- not understanding or speeking danish
- cognitive dysfunction
- chronic immobilization
- pregnancy
- diabetes (type I and II)
- Permanent atrial fibrillation or pacemaker
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Association Between Postoperative Glucose Profile, Sleep and Heart Rate Variability and Postoperative Complications in Patients Undergoing Acute, Abdominal Surgery. A Prospective, Explorative Cohort Study
The purpose of the study is to investigate whether glucose profile, sleep disturbances and heart rate variability measured with wearable devices is associated with postoperative recovery and complications within 30 days after major emergency abdominal surgery.
The study is designed as an explorative, prospective cohort study. 40 patients undergoing major emergency abdominal surgery at Zealand's University Hospital Køge are included in the study, and inclusion occurs within 24 hours of end of surgery. Patients will be followed for 30 days, and three scheduled study visits are planned during follow up at postoperative day 10, 20 and 30.
Read more
Glucose is measured continuously with a wearable subcutaneous sensor (Dexcom G6). Glucose readings are validated in the perioperative setting using blood glucose measurements obtained with standard finger-pricks 3-5 times a day during hospitalization.
Actigraphy is used for assessing sleep- and activity patterns for the full study period.
Heart rate variation is measured with a compact Holter monitor. Furthermore, the study assesses patient-reported quality of recovery, glucose metabolism, nutritional status and mobility. Various data on demographics, peri- and postoperative data will be extracted from the electronic patient chart.
Read the detailed description
Purpose:
The purpose of the study is to investigate the glucose-profile, HRV and sleep disturbances for 30 days after major emergency abdominal surgery using continues measurements with wearable devices. Secondly, the study investigates the association between glucose profile, HRV, sleep-disturbances, patient reported recovery and postoperative complications.
Design and study population:
The study is designed as a prospective, explorative cohort study applying repeated measures. Patients undergoing major emergency abdominal surgery at Zealand's University Hospital Køge are included. Included patients receive a standardized treatment regimen (Optimizing Major EmerGency Abdominal surgery, OMEGA), which has been established in the surgical department in order to reduce unnecessary waiting time and optimize and standardize treatment before, during and after major emergency abdominal surgery. The treatment regimen includes pre-operative antibiotics, I.V. fluid, pain and nausea treatment, nasogastric tube and prioritized, fast access to CT-scans and final surgical treatment.
Sample Size:
To the extent of our knowledge, no prior studies have simultaneously investigated sleep disturbances, heart rate variability and glucose profile using continues measurements with wearables before and up to 30 days after major emergency abdominal surgery. A traditional power calculation would be based on arbitrary data and is therefore omitted. Hence, the present study is designed as an exploratory study with no primary endpoint and functions as a pilot study prior to future larger, focused cohort studies. It is estimated, that inclusion of 40 patients in the present study is feasible and provides sufficient statistical power to show significant changes and association between glucose profile, HRV, sleep patterns and patient reported outcome measures.
Course of the study and assessment tools:
Eligible patients will be contacted by study investigators within 12-24 hours after surgery when the patient has been re-transferred to the surgical ward. Included patients will be followed for 30 days, and three scheduled study visits are planned during follow up at postoperative day 10, 20 and 30.
Glucose is measured continuously from the interstitial fluid of the subcutaneous tissue with a wearable subcutaneous sensor (Dexcom G6). Continues Glucose measurement (CGM) is normally used by diabetic patients in an outpatient setting. Therefore, the CGM readings are validated in the perioperative setting using capillary blood glucose measurements obtained with standard finger-pricks 3-5 times a day during hospitalization. The CGM-monitor is mounted on the patient from inclusion until 30 days after surgery. Metrics of within-day glycemic variability include the standard deviation (SD), the 'mean amplitude of glucose excursions' (MAGE) and the 'derived coefficient of variation' (%CV). Stable glucose levels are defined as a %CV <36% according to the international consensus on use of continues glucose monitoring. Metrics of between-day glucose variability include 'Mean of daily differences' (MODD), which is the absolute difference between two glucose values measured at the same time with a 24 h interval. Furthermore, the daily 'mean glucose level' and 'time in ranges' (TIRs) will be reported.
Actigraphy is used for measuring sleep- and activity patterns for the full study period. The device consists of three linear accelerometer with an integrated minicomputer that allows the direct measure of accelerations in all directions. In this study we will use the 'Zero-crossing method', where every acceleration (>0,1g) during each epoch length are measured. The epoch length in this study is predefined to 60 seconds. Metrics of sleep disturbances include 'Time in Bed' (TIB), 'Total Sleep Time' (TST), ' Sleep Efficiency' (SE), 'Wake Time' (WT) and 'Wake after Sleep Onset' (WASO), Sleep Latency (SL) and number of awakenings longer than five minutes" (NOA).
A battery powered, rechargeable heart rate monitor (C3 Holter monitor, Cortrium, Denmark) will be used for monitoring HRV. The device is a triangular monitor (7x7x7cm) and consist of three integrated electrodes allowing for measuring long term ECG. Data is stored on internal memory on the device and can be transferred to appropriate desktop software (Kubios Premium). Heart rate will be monitored from inclusion until 7 days after discharge or until postoperative day 14, whatever comes first. Time-domain analysis of HRV will be applied as recommended in the guidelines from the European Society of Cardiology and The North American Society of Pacing and Electrophysiology.
The widely used questionnaire quality of recovery-15 (QoR/15) quantifies patient reported quality of recovery with 15 Danish translated and validated questions. The questionnaire is completed in 2-3 minutes and results in a score up to 150 points with a high score indicating high self-reported postoperative recovery. The participants fills out QoR-15 every day during hospitalization and once at each scheduled study visit.
Estimation of pancreatic beta-cell functions and peripheral insulin resistance will be assessed with paired C-peptide and plasma glucose samples obtained at inclusion, discharge and 30-day follow up. In addition, changes in p-carbamide, hemoglobin, hemoglobin A1C, C-reactive protein and white blood cell count are measured during the study period.
A designated dietician assesses the patient's daily nutritional energy intake during hospitalization. In addition, the patient's nutritional consumption after discharge is estimated with the "24 hour recall method" at each follow up visit and the questionnaire "Food Frequency questionnaire" (FFQ), at 30 day follow up. In the FFQ-questionnaire, the patient reports the frequency of the consumption of 104 different common food and drink products during the last 30 days.
To assess changes in the patient's mobility the "Timed Up-and-go"-test will be used. Furthermore, 7 basic abilities during hospitalization (e.g. showering or dressing) are assessed on a scale from 0-2 with the questionnaire "Mobility during Hospitalization". After discharge, the questionnaire "Activity of Daily Living (ADL)" is used for assessing whether the patient is able to perform everyday activities (e.g. cooking, grossery shopping) on a 1-5 scale. In addition, handgrip strength, weight and bio impendence is measured at inclusion, at discharge and at each follow up visit.
Data on demographics, peri- and postoperative data will be extracted from the electronic patient chart. Postoperative complications will be classified according to the Clavien-Dindo classification.
To investigate the subjective experience of being discharged with three wearable monitors, a designated anthropologist conducts a semi-structured interview in a subgroup of 6-8 patients.
Statistics:
For baseline characteristics, descriptive statistics will be applied including reports of mean, standard deviation (SD), median and interquartile range (IQR) when appropriate. For comparison, chi^2 test and t-test will be applied. When data is not normally distributed, log-transformation will be used when possible. Further statistical methods include correlation analysis and logistic regression modelling with adjustment of relevant confounders. A two-tailed p-value of 0.05 is considered statistically significant. Designated statistical software will be used (e.g. R version 3.6.1, https://www.r-project.org/). A trained statistician will be consulted when analyzing data.
- Conditions
- Surgery--Complications, Abdomen Disease
- Keywords
- Wearables, Emergency surgery, Abdominal surgery, Patient reported outcome measures, Recovery, Continues Glucose Monitoring, Heart Rate Variation, Actigraphy, Sleep, Quality of Recovery
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Recovery-15 score
The score is based on 15 questions with a maximum total score of 150 indicating excellent patient-reported recovery
Measured: 30 days
Heart rate variation
Heart rate variation measured with wearable devices. Time domain measures are used.
Measured: 7 days post discharge or maximum 14 days after surgery
Total Sleep Time
Total time of sleep during 24 hours, assessed with actigraphy
Measured: 30 days
Sleep Efficiency
The ratio of the total sleep time compared to the total time spent in bed during 24 hours
Measured: 30 days
Mean amplitude of glucose excursions (MAGE)
Measure of within-day glycemic variability assessed with continues glucose monitoring
Measured: 30 days
Secondary outcomes (7)
Time in bed
total time in bed during 24 hours, assessed with actigraphy
Measured: 30 days
Wake Time
Time awake during 24 hours assessed with acitgraphy
Measured: 30 days
Wake after Sleep Onset (WASO)
Total time awake after sleep onset assessed with actigraphy
Measured: 30 days
Number of awakenings
Number of awakenings longer than five minutes assessed with actigraphy
Measured: 30 days
Time in range
The total time during 24 hours where the patient is normoglycemic, assessed with continues glucose monitoring
Measured: 30 days
Mean glucose level
The mean glucose level during 24 hours assessed with continues glucose monitoring
Measured: 30 days
Derived coefficient of glucose variation (%CV)
Measure of within-day glycemic variability
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2020
- Study start1 Oct 2019
- Primary completion22 Jan 2021
- Study completion20 Feb 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Surgery--ComplicationsStudies of the same condition, open and under way.
- More trials run by Zealand University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zealand University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Johan Johan, MD, Principal investigator, Surgical department, Zealands University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04257344
- Sponsor's protocol ID
- REG-071-2019
- Status last verified
- Sep 2021
- First submitted
- 11 Dec 2019
- Last updated
- 21 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Monnier L, Colette C, Owens DR. The application of simple metrics in the assessment of glycaemic variability. Diabetes Metab. 2018 Sep;44(4):313-319. doi: 10.1016/j.diabet.2018.02.008. Epub 2018 Mar 6.
PubMed 29602622Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Norgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017 Dec;40(12):1631-1640. doi: 10.2337/dc17-1600.
PubMed 29162583Berger AM, Wielgus KK, Young-McCaughan S, Fischer P, Farr L, Lee KA. Methodological challenges when using actigraphy in research. J Pain Symptom Manage. 2008 Aug;36(2):191-9. doi: 10.1016/j.jpainsymman.2007.10.008. Epub 2008 Apr 8.
PubMed 18400460Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996 Mar;17(3):354-81. No abstract available.
PubMed 8737210Gornall BF, Myles PS, Smith CL, Burke JA, Leslie K, Pereira MJ, Bost JE, Kluivers KB, Nilsson UG, Tanaka Y, Forbes A. Measurement of quality of recovery using the QoR-40: a quantitative systematic review. Br J Anaesth. 2013 Aug;111(2):161-9. doi: 10.1093/bja/aet014. Epub 2013 Mar 6.
PubMed 23471753Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004 Jun;27(6):1487-95. doi: 10.2337/diacare.27.6.1487.
PubMed 15161807Beer-Borst S, Amado R. Validation of a self-administered 24-hour recall questionnaire used in a large-scale dietary survey. Z Ernahrungswiss. 1995 Sep;34(3):183-9. doi: 10.1007/BF01623156.
PubMed 7502539Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991 Feb;39(2):142-8. doi: 10.1111/j.1532-5415.1991.tb01616.x.
PubMed 1991946
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association Between Postoperative Glucose Profile, Sleep and Heart Rate Variability and Postoperative Complications in Patients Undergoing Acute, Abdominal Surgery. A Prospective, Explorative Cohort Study
- ClinicalTrials.gov ID
- NCT04257344
- Acronym / sponsor ID
- REG-071-2019
- Conditions
- Surgery--Complications, Abdomen Disease
- Keywords
- Wearables, Emergency surgery, Abdominal surgery, Patient reported outcome measures, Recovery, Continues Glucose Monitoring, Heart Rate Variation, Actigraphy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Zealand University HospitalUniversity, hospital or other
- Study start
- 1 Oct 2019 (actual)
- Primary completion
- 22 Jan 2021 (actual)
- Study completion
- 20 Feb 2021 (actual)
- First posted
- 6 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to investigate whether glucose profile, sleep disturbances and heart rate variability measured with wearable devices is associated with postoperative recovery and complications within 30 days after major emergency abdominal surgery.
The study is designed as an explorative, prospective cohort study. 40 patients undergoing major emergency abdominal surgery at Zealand's University Hospital Køge are included in the study, and inclusion occurs within 24 hours of end of surgery. Patients will be followed for 30 days, and three scheduled study visits are planned during follow up at postoperative day 10, 20 and 30.
Glucose is measured continuously with a wearable subcutaneous sensor (Dexcom G6). Glucose readings are validated in the perioperative setting using blood glucose measurements obtained with standard finger-pricks 3-5 times a day during hospitalization.
Actigraphy is used for assessing sleep- and activity patterns for the full study period.
Heart rate variation is measured with a compact Holter monitor. Furthermore, the study assesses patient-reported quality of recovery, glucose metabolism, nutritional status and mobility. Various data on demographics, peri- and postoperative data will be extracted from the electronic patient chart.
Detailed description
Purpose:
The purpose of the study is to investigate the glucose-profile, HRV and sleep disturbances for 30 days after major emergency abdominal surgery using continues measurements with wearable devices. Secondly, the study investigates the association between glucose profile, HRV, sleep-disturbances, patient reported recovery and postoperative complications.
Design and study population:
The study is designed as a prospective, explorative cohort study applying repeated measures. Patients undergoing major emergency abdominal surgery at Zealand's University Hospital Køge are included. Included patients receive a standardized treatment regimen (Optimizing Major EmerGency Abdominal surgery, OMEGA), which has been established in the surgical department in order to reduce unnecessary waiting time and optimize and standardize treatment before, during and after major emergency abdominal surgery. The treatment regimen includes pre-operative antibiotics, I.V. fluid, pain and nausea treatment, nasogastric tube and prioritized, fast access to CT-scans and final surgical treatment.
Sample Size:
To the extent of our knowledge, no prior studies have simultaneously investigated sleep disturbances, heart rate variability and glucose profile using continues measurements with wearables before and up to 30 days after major emergency abdominal surgery. A traditional power calculation would be based on arbitrary data and is therefore omitted. Hence, the present study is designed as an exploratory study with no primary endpoint and functions as a pilot study prior to future larger, focused cohort studies. It is estimated, that inclusion of 40 patients in the present study is feasible and provides sufficient statistical power to show significant changes and association between glucose profile, HRV, sleep patterns and patient reported outcome measures.
Course of the study and assessment tools:
Eligible patients will be contacted by study investigators within 12-24 hours after surgery when the patient has been re-transferred to the surgical ward. Included patients will be followed for 30 days, and three scheduled study visits are planned during follow up at postoperative day 10, 20 and 30.
Glucose is measured continuously from the interstitial fluid of the subcutaneous tissue with a wearable subcutaneous sensor (Dexcom G6). Continues Glucose measurement (CGM) is normally used by diabetic patients in an outpatient setting. Therefore, the CGM readings are validated in the perioperative setting using capillary blood glucose measurements obtained with standard finger-pricks 3-5 times a day during hospitalization. The CGM-monitor is mounted on the patient from inclusion until 30 days after surgery. Metrics of within-day glycemic variability include the standard deviation (SD), the 'mean amplitude of glucose excursions' (MAGE) and the 'derived coefficient of variation' (%CV). Stable glucose levels are defined as a %CV <36% according to the international consensus on use of continues glucose monitoring. Metrics of between-day glucose variability include 'Mean of daily differences' (MODD), which is the absolute difference between two glucose values measured at the same time with a 24 h interval. Furthermore, the daily 'mean glucose level' and 'time in ranges' (TIRs) will be reported.
Actigraphy is used for measuring sleep- and activity patterns for the full study period. The device consists of three linear accelerometer with an integrated minicomputer that allows the direct measure of accelerations in all directions. In this study we will use the 'Zero-crossing method', where every acceleration (>0,1g) during each epoch length are measured. The epoch length in this study is predefined to 60 seconds. Metrics of sleep disturbances include 'Time in Bed' (TIB), 'Total Sleep Time' (TST), ' Sleep Efficiency' (SE), 'Wake Time' (WT) and 'Wake after Sleep Onset' (WASO), Sleep Latency (SL) and number of awakenings longer than five minutes" (NOA).
A battery powered, rechargeable heart rate monitor (C3 Holter monitor, Cortrium, Denmark) will be used for monitoring HRV. The device is a triangular monitor (7x7x7cm) and consist of three integrated electrodes allowing for measuring long term ECG. Data is stored on internal memory on the device and can be transferred to appropriate desktop software (Kubios Premium). Heart rate will be monitored from inclusion until 7 days after discharge or until postoperative day 14, whatever comes first. Time-domain analysis of HRV will be applied as recommended in the guidelines from the European Society of Cardiology and The North American Society of Pacing and Electrophysiology.
The widely used questionnaire quality of recovery-15 (QoR/15) quantifies patient reported quality of recovery with 15 Danish translated and validated questions. The questionnaire is completed in 2-3 minutes and results in a score up to 150 points with a high score indicating high self-reported postoperative recovery. The participants fills out QoR-15 every day during hospitalization and once at each scheduled study visit.
Estimation of pancreatic beta-cell functions and peripheral insulin resistance will be assessed with paired C-peptide and plasma glucose samples obtained at inclusion, discharge and 30-day follow up. In addition, changes in p-carbamide, hemoglobin, hemoglobin A1C, C-reactive protein and white blood cell count are measured during the study period.
A designated dietician assesses the patient's daily nutritional energy intake during hospitalization. In addition, the patient's nutritional consumption after discharge is estimated with the "24 hour recall method" at each follow up visit and the questionnaire "Food Frequency questionnaire" (FFQ), at 30 day follow up. In the FFQ-questionnaire, the patient reports the frequency of the consumption of 104 different common food and drink products during the last 30 days.
To assess changes in the patient's mobility the "Timed Up-and-go"-test will be used. Furthermore, 7 basic abilities during hospitalization (e.g. showering or dressing) are assessed on a scale from 0-2 with the questionnaire "Mobility during Hospitalization". After discharge, the questionnaire "Activity of Daily Living (ADL)" is used for assessing whether the patient is able to perform everyday activities (e.g. cooking, grossery shopping) on a 1-5 scale. In addition, handgrip strength, weight and bio impendence is measured at inclusion, at discharge and at each follow up visit.
Data on demographics, peri- and postoperative data will be extracted from the electronic patient chart. Postoperative complications will be classified according to the Clavien-Dindo classification.
To investigate the subjective experience of being discharged with three wearable monitors, a designated anthropologist conducts a semi-structured interview in a subgroup of 6-8 patients.
Statistics:
For baseline characteristics, descriptive statistics will be applied including reports of mean, standard deviation (SD), median and interquartile range (IQR) when appropriate. For comparison, chi^2 test and t-test will be applied. When data is not normally distributed, log-transformation will be used when possible. Further statistical methods include correlation analysis and logistic regression modelling with adjustment of relevant confounders. A two-tailed p-value of 0.05 is considered statistically significant. Designated statistical software will be used (e.g. R version 3.6.1, https://www.r-project.org/). A trained statistician will be consulted when analyzing data.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- the study population consists of all patients admitted at Zealands University Hospital Køge, who undergo major emergency abdominal surgery.
Key inclusion criteria (1 listed)
- Patients undergoing major emergency abdominal surgery including laparotomy or laporoscopy. Indications include ileus, perforated hollow organ, intraabdominal bleeding, ischemia, wound dehiscence.
Key exclusion criteria (7 listed)
- Laparoscopic surgeries for diseases related to appendix, gall bladder or bile ducts are excluded, unless the procedure is converted to open surgery perioperative.
- not understanding or speeking danish
- cognitive dysfunction
- chronic immobilization
- pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Quality of Recovery-15 score
Time frame: 30 days
The score is based on 15 questions with a maximum total score of 150 indicating excellent patient-reported recovery
Heart rate variation
Time frame: 7 days post discharge or maximum 14 days after surgery
Heart rate variation measured with wearable devices. Time domain measures are used.
Total Sleep Time
Time frame: 30 days
Total time of sleep during 24 hours, assessed with actigraphy
Sleep Efficiency
Time frame: 30 days
The ratio of the total sleep time compared to the total time spent in bed during 24 hours
Mean amplitude of glucose excursions (MAGE)
Time frame: 30 days
Measure of within-day glycemic variability assessed with continues glucose monitoring
7 secondary outcomes
Time in bed
Time frame: 30 days
Wake Time
Time frame: 30 days
Wake after Sleep Onset (WASO)
Time frame: 30 days
Number of awakenings
Time frame: 30 days
Time in range
Time frame: 30 days
Mean glucose level
Time frame: 30 days
Derived coefficient of glucose variation (%CV)
Time frame: 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2021.
- Background: PubMed 29602622Monnier L, Colette C, Owens DR. The application of simple metrics in the assessment of glycaemic variability. Diabetes Metab. 2018 Sep;44(4):313-319. doi: 10.1016/j.diabet.2018.02.008. Epub 2018 Mar 6.
- Background: PubMed 29162583Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Norgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017 Dec;40(12):1631-1640. doi: 10.2337/dc17-1600.
- Background: PubMed 18400460Berger AM, Wielgus KK, Young-McCaughan S, Fischer P, Farr L, Lee KA. Methodological challenges when using actigraphy in research. J Pain Symptom Manage. 2008 Aug;36(2):191-9. doi: 10.1016/j.jpainsymman.2007.10.008. Epub 2008 Apr 8.
- Background: PubMed 8737210Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996 Mar;17(3):354-81. No abstract available.
- Background: PubMed 23471753Gornall BF, Myles PS, Smith CL, Burke JA, Leslie K, Pereira MJ, Bost JE, Kluivers KB, Nilsson UG, Tanaka Y, Forbes A. Measurement of quality of recovery using the QoR-40: a quantitative systematic review. Br J Anaesth. 2013 Aug;111(2):161-9. doi: 10.1093/bja/aet014. Epub 2013 Mar 6.
- Background: PubMed 15161807Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004 Jun;27(6):1487-95. doi: 10.2337/diacare.27.6.1487.
- Background: PubMed 7502539Beer-Borst S, Amado R. Validation of a self-administered 24-hour recall questionnaire used in a large-scale dietary survey. Z Ernahrungswiss. 1995 Sep;34(3):183-9. doi: 10.1007/BF01623156.
- Background: PubMed 1991946Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991 Feb;39(2):142-8. doi: 10.1111/j.1532-5415.1991.tb01616.x.
Related trials for Surgery--Complications
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
Recruiting
Change in Platelet Lipid Metabolism and Procoagulant Phenotype Induced by Cardiopulmonary Bypass. Impact on Postoperative Inflammatory Response and Bleeding Complications During Cardiac Surgery.
Cardiac Surgery, Cardiopulmonary Bypass
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Recruiting
Prospective, Multicenter, Randomized Controlled Phase III Trial of Biological Mesh for Alimentary Tract Reconstruction in Digestive Surgery
Digestive System Surgical Procedures, Anastomosis, Surgical
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Johan Johan, MD principal investigator
Surgical department, Zealands University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Surgery--Complications and Abdomen Disease, run by Zealand University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of Recovery-15 score (time frame: 30 days). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04257344, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2021.